| Symbol | Company | Owner | Relationship | Date | Transaction | Cost | # Shares | Value ($) | Total Shares | Filing | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Mar 18, 2024 | Sale | $5.04 | 9,361 | 47,204 | 192,666 | Mar 19, 2024, 06:44 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Mar 15, 2024 | Option Exercise | $5.30 | 3,822 | 20,276 | 202,027 | Mar 19, 2024, 06:44 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Aug 11, 2023 | Option Exercise | $18.91 | 11,215 | 212,076 | 91,301 | Aug 15, 2023, 04:16 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jun 30, 2023 | Option Exercise | $15.61 | 769 | 12,001 | 81,597 | Jul 05, 2023, 09:11 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jul 03, 2023 | Sale | $25.04 | 1,701 | 42,593 | 79,896 | Jul 05, 2023, 09:11 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jun 02, 2023 | Sale | $31.00 | 500 | 15,500 | 80,828 | Jun 05, 2023, 06:06 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jun 01, 2023 | Sale | $30.57 | 2,701 | 82,570 | 81,328 | Jun 05, 2023, 06:06 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | May 15, 2023 | Sale | $34.55 | 21,401 | 739,338 | 84,029 | May 16, 2023, 08:29 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | May 01, 2023 | Sale | $31.70 | 3,201 | 101,472 | 63,081 | May 02, 2023, 04:01 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Apr 03, 2023 | Sale | $32.15 | 3,201 | 102,912 | 66,282 | Apr 04, 2023, 04:24 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Mar 15, 2023 | Option Exercise | $30.65 | 3,739 | 114,600 | 69,483 | Mar 17, 2023, 03:21 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Mar 09, 2023 | Sale | $31.59 | 18,517 | 584,884 | 73,222 | Mar 09, 2023, 09:46 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Mar 01, 2023 | Sale | $33.50 | 3,201 | 107,234 | 49,390 | Mar 02, 2023, 09:25 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Feb 15, 2023 | Option Exercise | $33.21 | 2,085 | 69,243 | 52,591 | Feb 16, 2023, 08:28 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Feb 01, 2023 | Sale | $34.60 | 3,201 | 110,755 | 54,676 | Feb 02, 2023, 09:38 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jan 20, 2023 | Sale | $31.00 | 1,000 | 31,000 | 57,877 | Jan 23, 2023, 05:35 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jan 09, 2023 | Sale | $27.16 | 3,701 | 100,525 | 60,877 | Jan 10, 2023, 08:06 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 31, 2022 | Option Exercise | $12.18 | 645 | 7,856 | 62,578 | Jan 03, 2023, 04:29 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 15, 2022 | Option Exercise | $21.50 | 1,557 | 33,476 | 61,933 | Dec 16, 2022, 04:12 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jun 30, 2022 | Option Exercise | $11.75 | 965 | 11,336 | 63,490 | Jul 05, 2022, 06:15 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | Chief Financial Officer | Mar 15, 2022 | Option Exercise | $15.79 | 2,607 | 41,165 | 62,525 | Mar 17, 2022, 05:48 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Feb 15, 2022 | Option Exercise | $13.35 | 2,924 | 39,035 | 65,815 | Feb 17, 2022, 08:49 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 31, 2021 | Option Exercise | $13.87 | 404 | 5,604 | 68,056 | Jan 04, 2022, 08:58 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 15, 2021 | Option Exercise | $15.92 | 1,556 | 24,772 | 67,652 | Dec 17, 2021, 05:31 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jun 30, 2021 | Option Exercise | $24.09 | 446 | 10,744 | 69,208 | Jul 02, 2021, 07:53 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Feb 15, 2021 | Option Exercise | $28.97 | 2,657 | 76,973 | 70,735 | Feb 19, 2021, 08:15 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 31, 2020 | Option Exercise | $21.36 | 493 | 10,531 | 48,799 | Jan 04, 2021, 08:02 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 15, 2020 | Option Exercise | $26.75 | 1,556 | 41,623 | 48,306 | Dec 22, 2020, 08:39 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Sep 30, 2020 | Option Exercise | $25.14 | 5,446 | 136,912 | 49,862 | Oct 02, 2020, 08:32 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jun 30, 2020 | Option Exercise | $13.80 | 763 | 10,526 | 39,558 | Jul 02, 2020, 08:18 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Feb 15, 2020 | Option Exercise | $25.33 | 576 | 14,590 | 38,795 | Feb 19, 2020, 08:21 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 31, 2019 | Option Exercise | $10.82 | 504 | 5,453 | 22,871 | Jan 03, 2020, 06:42 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 15, 2019 | Option Exercise | $15.99 | 1,556 | 24,880 | 22,367 | Dec 17, 2019, 07:57 PM | |
| RVNC | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jun 28, 2019 | Option Exercise | $11.02 | 923 | 10,176 | 23,923 | Jul 02, 2019, 09:16 PM | |
| AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Officer | Jun 26, 2018 | Sale | $9.59 | 298 | 2,858 | 47,748 | Jun 28, 2018, 04:20 PM | |
| AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Officer | Jun 11, 2018 | Sale | $11.95 | 2,087 | 24,940 | 47,186 | Jun 13, 2018, 05:03 PM | |
| AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Officer | Feb 21, 2018 | Sale | $10.67 | 1,108 | 11,822 | 40,185 | Feb 23, 2018, 08:38 PM | |
| AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Officer | Jun 12, 2017 | Sale | $21.53 | 2,066 | 44,481 | 40,119 | Jun 14, 2017, 07:39 PM | |
| AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Officer | Jan 26, 2017 | Sale | $16.78 | 955 | 16,025 | 26,045 | Jan 30, 2017, 09:38 PM |
Menu